Gilead Sciences Inc.’s revenue rose 17% in the third quarter, helped by sales of its antiviral drug remdesivir that has become a standard treatment for hospitalized Covid-19 patients.

Yet sales of the company’s other drugs were hurt by pandemic-related shutdowns. And the company dialed back its forecast for overall revenue this year because of lower-than-expected hospitalization rates of Covid-19 patients.

Remdesivir,…

This post first appeared on wsj.com

You May Also Like

Michigan officer to face murder charge in fatal shooting of Patrick Lyoya, prosecutor announces

A Michigan prosecutor has charged a Grand Rapids police officer who fatally…

The Elizabeth Holmes Trial: Closing Arguments Begin

SAN JOSE, Calif.—Closing arguments begin Thursday in Elizabeth Holmes’s criminal-fraud trial, marking…

Sixth person dies from injuries days after Pennsylvania house explosion

PLUM, Pa. — The co-owner of a home that exploded in western…

Quibi Says Elliott’s Support of Patent Lawsuit Might Have Personal Motive

Defunct streaming service Quibi is trying to force executives at Elliott Management…